Great news for both patients, physicians and of course welcome news for Novo Nordisk now since FDA has approved Rybelsus, the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)
Dietary guidance that fits your life Oshi registered dietitians can help you identify foods that could be making your GLP-1 side effects worse
Independent baseline testing ensures you begin therapy with a complete clinical picture
It does not create a caloric deficit or override thermodynamics
We always put your overall well-being first, from the moment you arrive for treatment until you achieve sustainable results
GLP-1 receptor agonists slow gastrointestinal transit time